Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Portfolio Pulse from
Nexalin Technology has received a Notice of Allowance from the USPTO for a patent on its Deep Intracranial Frequency Stimulation (DIFS™) technology, aimed at treating substance use disorders. This strengthens Nexalin's intellectual property portfolio and highlights the potential of DIFS™ in addressing disorders related to opioids, alcohol, cocaine, and methamphetamine.
March 03, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology's receipt of a USPTO patent for its DIFS™ technology could enhance its market position by strengthening its intellectual property portfolio and showcasing its potential in treating substance use disorders.
The patent approval is a significant milestone for Nexalin Technology, as it not only strengthens its intellectual property portfolio but also highlights the potential of its DIFS™ technology in a critical area of healthcare. This could lead to increased investor confidence and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100